Table of Contents
ISRN Pediatrics
Volume 2014, Article ID 758343, 6 pages
http://dx.doi.org/10.1155/2014/758343
Clinical Study

Influence of the Type of Basal Insulin and Other Variables on Clinical Outcomes in Children with Newly Diagnosed Type 1 Diabetes

1Ambulatory Care, Veterans Affairs Medical Center, 921 NE 13th Street, Oklahoma City, OK 73104, USA
2Department of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, 4502 East 41st Street, Suite 1H05, Tulsa, OK 74135, USA
3Department of Pediatrics, University of Oklahoma School of Community Medicine, 4502 East 41st Street, Tulsa, OK 74135, USA
4Department of Pharmacy, Clinical and Administrative Sciences-Tulsa, University of Oklahoma College of Pharmacy, P.O. Box 26901, Oklahoma City, OK 73126, USA
5Harold Hamm Oklahoma Diabetes Center, Tulsa Program, University of Oklahoma School of Community Medicine, 4502 East 41st Street, Tulsa, OK 74135, USA

Received 20 October 2013; Accepted 26 December 2013; Published 6 February 2014

Academic Editors: D. V. Milford, O. Mishra, H. Neville, S. A. Sarker, and B. Vasarhelyi

Copyright © 2014 Ruth M. Garrison et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Monami, N. Marchionni, and E. Mannucci, “Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis,” Diabetes, Obesity and Metabolism, vol. 11, no. 4, pp. 372–378, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. “American Diabetes Association: position statement. Standards of medical care in diabetes—2013,” Diabetes Care, vol. 36, no. 1, pp. S11–S66, 2013.
  3. F. Porcellati, P. Rossetti, N. R. Busciantella et al., “Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes,” Diabetes Care, vol. 30, pp. 2447–2452, 2007. View at Google Scholar
  4. H. L. Miles and C. L. Acerini, “Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus,” Pediatric Drugs, vol. 10, no. 3, pp. 163–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Heise, L. Nosek, B. B. Roønn et al., “Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes,” Diabetes, vol. 53, no. 6, pp. 1614–1620, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Dann, N. Datz, L. Endahl et al., “Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial,” Pediatric Diabetes, vol. 9, no. 6, pp. 554–560, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. R. Pieber, H.-C. Treichel, B. Hompesch et al., “Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy,” Diabetic Medicine, vol. 24, no. 6, pp. 635–642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Yenigun and M. Honka, “Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study,” International Journal of Clinical Practice, vol. 63, no. 3, pp. 425–432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. U. M. Kabadi, “Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus,” Clinical Drug Investigation, vol. 28, no. 11, pp. 697–701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Rewers, C. Pihoker, K. Donaghue, R. Hanas, P. Swift, and G. J. Klingensmith, “Assessment and monitoring of glycemic control in children and adolescents with diabetes,” Pediatric Diabetes, vol. 10, no. 12, pp. 71–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. H. Aly and P. Gottlieb, “The honeymoon phase: intersection of metabolism and immunology,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 16, no. 4, pp. 286–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. S. Borus and L. Laffel, “Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention,” Current Opinion in Pediatrics, vol. 22, no. 4, pp. 405–411, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Hassan and R. A. Heptulla, “Glycemic control in pediatric type 1 diabetes: role of caregiver literacy,” Pediatrics, vol. 125, no. 5, pp. e1104–e1108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. B.-S. Levine, B. J. Anderson, D. A. Butler, J. E. Antisdel, J. Brackett, and L. M. B. Laffel, “Predictors of glycemic control and short-term adverse outcomes in youth with type 1 diabetes,” Journal of Pediatrics, vol. 139, no. 2, pp. 197–203, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Nimri, Y. Lebenthal, S. Shalitin, H. Benzaquen, S. Demol, and M. Phillip, “Metabolic control of insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes,” Pediatric Diabetes, vol. 14, no. 3, pp. 196–202, 2013. View at Publisher · View at Google Scholar
  16. S. Kurtoglu, M. E. Atabek, C. Dizdarer et al., “Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study,” Pediatric Diabetes, vol. 10, no. 6, pp. 401–407, 2009. View at Publisher · View at Google Scholar · View at Scopus